Access our exclusive content
  • Small Caps
    Mining Energy Biotech Technology Juniors
  • Opinion
    The 420 Report The Green Keeper Speculate Buy and Cell Ctrl Alt Del Q&A Startups Market Wrap
  • Features
  • Property
  • Investor 101
  • Podcasts
  • Stock of the Week
  • Trifecta
  • Small Caps
    Mining Energy Biotech Technology Juniors
  • Opinion
    The 420 Report The Green Keeper Speculate Buy and Cell Ctrl Alt Del Q&A Startups Market Wrap
  • Features
  • Property
  • Investor 101
  • Podcasts
  • Stock of the Week
  • Trifecta
Keep me posted menu

Immuron Limited (ASX:IMC)

November 19th

Immuron appoints a new CEO to lead it into the future

Immuron’s Travelan® protects against Shigella in primates

September 5th 2018

Immuron’s Travelan® protects against Shigella in primates

Immuron generates strong Travelan sales growth

July 25th 2018

Immuron generates strong Travelan sales growth

US Defense finishes latest research on Immuron’s Travelan®

July 16th 2018

US Defense finishes latest research on Immuron’s Travelan®

Immuron Announces A$5.1M Private Placement to U.S. Fund

March 14th 2018

Immuron Announces A$5.1M Private Placement to U.S. Fund

Results in: IMC’s lead drug reduces major factor in liver inflammation

March 8th 2018

Results in: IMC’s lead drug reduces major factor in liver inflammation

Big spike in sales growth for IMC’s Travelan® product

February 16th 2018

Big spike in sales growth for IMC’s Travelan® product

Broker sees substantial upside in Immuron with catalysts imminent

October 25th 2017

Broker sees substantial upside in Immuron with catalysts imminent

Immuron takes another step towards addressing US$10 billion CDI market

August 28th 2017

Immuron takes another step towards addressing US$10 billion CDI market

Immuron gets go-ahead for finalisation of IMM-124E trials

July 11th 2017

Immuron gets go-ahead for finalisation of IMM-124E trials

Sales of Immuron’s Travelan up 13% as it considers geographic expansion

June 2nd 2017

Sales of Immuron’s Travelan up 13% as it considers geographic expansion

Immuron expands collaboration with US Department of Defence

May 17th 2017

Immuron expands collaboration with US Department of Defence

Immuron completes manufacturing trial supplies of IMM-529

May 10th 2017

Immuron completes manufacturing trial supplies of IMM-529

Immuron completes first stage of colitis preclinical program

April 18th 2017

Immuron completes first stage of colitis preclinical program

Clinical studies could provide market moving news for Immuron in 2017

April 7th 2017

Clinical studies could provide market moving news for Immuron in 2017

Immuron targets the gut not the liver

March 30th 2017

Immuron targets the gut not the liver

Connect with us

Catalysts Imminent as NIC Eyes Full Scale Nickel Production
Get our newsletter sent straight to your inbox
© 2019 Finfeed.com. All Rights Reserved.
  • customer notice
  • privacy policy
  • financial services guide
  • disclosure policy
  • social media influencer policy
  • contact

The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).